IMCR Immunocore Holdings Ltd

$36.57

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/18/2025

About Immunocore Holdings Ltd

Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.

Website: https://www.immunocore.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1671927
Address
92 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, GB
Valuation
Market Cap
$1.40B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
3.89
Performance
EPS
$-1.02
Dividend Yield
—
Profit Margin
-16.50%
ROE
-14.00%
Technicals
50D MA
$28.92
200D MA
$32.34
52W High
$62.74
52W Low
$23.15
Fundamentals
Shares Outstanding
49M
Target Price
$63.39
Beta
0.76

IMCR EPS Estimates vs Actual

● Estimated
● Actual

IMCR News & Sentiment

Nov 07, 2025 • GlobeNewswire NEUTRAL
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity ...
Nov 06, 2025 • GlobeNewswire NEUTRAL
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update KIMMTRAK® ( tebentafusp-tebn ) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026
Nov 03, 2025 • Zacks Commentary NEUTRAL
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
Sep 16, 2025 • Benzinga SOMEWHAT-BULLISH
Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer
CHICAGO, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing transformative therapies for patients with rare and life-threatening diseases, today announced the appointment of Dr. Shaad Abedin as Chief Medical Officer.
Sep 10, 2025 • GlobeNewswire NEUTRAL
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025
Oslo, Norway, 10 September 2025 - Zelluna ( OSE: ZLNA ) , a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer ( TCR-NK ) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at ...
Aug 08, 2025 • Zacks Commentary NEUTRAL
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Sentiment Snapshot

Average Sentiment Score:

0.083
50 articles with scored sentiment

Overall Sentiment:

Neutral

IMCR Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.18
  • Whisper: —
  • Surprise %: -11.1%
May 07, 2025
Mar 31, 2025 (Pre market)
-0.13 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: -36.1%
Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.21 Surprise
  • Reported EPS: $-0.37
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: -133.0%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.52 Surprise
  • Reported EPS: $0.17
  • Estimate: $-0.35
  • Whisper: —
  • Surprise %: 148.6%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.25 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.48
  • Whisper: —
  • Surprise %: 52.1%
May 08, 2024
Mar 31, 2024 (Pre market)
-0.13 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: -36.1%
Feb 28, 2024
Dec 31, 2023 (Pre market)
-10.48 Surprise
  • Reported EPS: $-32.22
  • Estimate: $-21.74
  • Whisper: —
  • Surprise %: -48.2%
Nov 07, 2023
Sep 30, 2023 (Pre market)
32.92 Surprise
  • Reported EPS: $4.00
  • Estimate: $-28.92
  • Whisper: —
  • Surprise %: 113.8%
Aug 10, 2023
Jun 30, 2023 (Pre market)
31.73 Surprise
  • Reported EPS: $-0.37
  • Estimate: $-32.10
  • Whisper: —
  • Surprise %: 98.8%

Financials